These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 28475276)

  • 1. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
    Funk RS; Chan MA; Becker ML
    Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
    Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
    J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
    Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
    Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.
    Khraishi M; Millson B; Woolcott J; Jones H; Marshall L; Ruperto N
    Pediatr Rheumatol Online J; 2019 Sep; 17(1):64. PubMed ID: 31500631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA).
    Kaminiarczyk-Pyzalka D; Adamczak K; Mikos H; Klimecka I; Moczko J; Niedziela M
    Clin Lab; 2014; 60(9):1481-90. PubMed ID: 25291944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
    Su Y; Yang YH; Chiang BL
    Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
    Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
    Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study.
    Levälampi T; Kärki J; Rebane K; Vähäsalo P; Malin M; Kröger L; Grönlund MM; Backström M; Pohjankoski H; Kautiainen H; Jokiranta S; Aalto K
    Pediatr Rheumatol Online J; 2023 Mar; 21(1):27. PubMed ID: 36949461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis.
    Bulatović Ćalasan M; Vastert SJ; Scholman RC; Verweij F; Klein M; Wulffraat NM; Prakken BJ; van Wijk F
    Rheumatology (Oxford); 2015 Sep; 54(9):1724-34. PubMed ID: 25877908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
    Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
    Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
    Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
    Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
    van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
    Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
    Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
    De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
    J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients.
    Spîrchez M; Samaşca G; Iancu M; Bolba C; Miu N
    Clin Lab; 2012; 58(3-4):253-60. PubMed ID: 22582498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
    Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
    Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.
    Fráňová J; Fingerhutová Š; Kobrová K; Srp R; Němcová D; Hoza J; Uher M; Saifridová M; Linková L; Doležalová P
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):36. PubMed ID: 27301536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.